{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:41:56Z","timestamp":1777675316631,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30\u2009days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70\u2009years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies\/ml (48.5% vs 22.9%) than non-treated group (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307, 95% CI 0.759\u20132.251) and 12-months survival (HR 1.533, 95% CI 0.895\u20132.624).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06098-4","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T10:03:07Z","timestamp":1620122587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation"],"prefix":"10.1186","volume":"21","author":[{"given":"Ga Eun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Kyun","family":"Ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"12","key":"6098_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","volume":"4","author":"MK Gandhi","year":"2004","unstructured":"Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725\u201338.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"6098_CR2","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10096-014-2107-x","volume":"33","author":"JH Ko","year":"2014","unstructured":"Ko JH, Peck KR, Lee WJ, Huh K, Yoo JR, Kim K, et al. Risk factors for cytomegalovirus gastrointestinal diseases in adult patients with cancer. Eur J Clin Microbiol Infect Dis. 2014;33(10):1847\u201353.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"6098_CR3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3201\/eid1210.060411","volume":"12","author":"L von Muller","year":"2006","unstructured":"von Muller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis. 2006;12(10):1517\u201322.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"6098_CR4","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1097\/CCM.0b013e31819ffea6","volume":"37","author":"L Chiche","year":"2009","unstructured":"Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, Allardet-Servent J, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37(6):1850\u20137.","journal-title":"Crit Care Med"},{"issue":"3","key":"6098_CR5","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/cc7875","volume":"13","author":"R Osawa","year":"2009","unstructured":"Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13(3):R68.","journal-title":"Crit Care"},{"issue":"1","key":"6098_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1378\/chest.127.1.233","volume":"127","author":"S Jaber","year":"2005","unstructured":"Jaber S, Chanques G, Borry J, Souche B, Verdier R, Perrigault PF, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest. 2005;127(1):233\u201341.","journal-title":"Chest"},{"issue":"3","key":"6098_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00134-015-4071-z","volume":"42","author":"DS Ong","year":"2016","unstructured":"Ong DS, Spitoni C, Klein Klouwenberg PM, Verduyn Lunel FM, Frencken JF, Schultz MJ, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42(3):333\u201341.","journal-title":"Intensive Care Med"},{"issue":"4","key":"6098_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jama.300.4.413","volume":"300","author":"AP Limaye","year":"2008","unstructured":"Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. Jama. 2008;300(4):413\u201322.","journal-title":"Jama"},{"issue":"1","key":"6098_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00134-015-4066-9","volume":"42","author":"L Papazian","year":"2016","unstructured":"Papazian L, Hraiech S, Lehingue S, Roch A, Chiche L, Wiramus S, et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med. 2016;42(1):28\u201337.","journal-title":"Intensive Care Med"},{"issue":"3","key":"6098_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00003246-200103000-00012","volume":"29","author":"A Heininger","year":"2001","unstructured":"Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med. 2001;29(3):541\u20137.","journal-title":"Crit Care Med"},{"key":"6098_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1743-422X-5-47","volume":"5","author":"PI Rafailidis","year":"2008","unstructured":"Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47.","journal-title":"Virol J"},{"issue":"6","key":"6098_CR12","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1093\/cid\/ciu969","volume":"60","author":"JH Ko","year":"2015","unstructured":"Ko JH, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, et al. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. Clin Infect Dis. 2015;60(6):e20\u20136.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6098_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000427","volume":"5","author":"J Cheng","year":"2009","unstructured":"Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009;5(5):e1000427.","journal-title":"PLoS Pathog"},{"issue":"12","key":"6098_CR14","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00134-014-3445-y","volume":"40","author":"J-M Forel","year":"2014","unstructured":"Forel J-M, Martin-Loeches I, Luyt C-E. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro. Intensive Care Med. 2014;40(12):1945\u20139.","journal-title":"Intensive Care Med"},{"issue":"8","key":"6098_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1086\/339329","volume":"34","author":"P Ljungman","year":"2002","unstructured":"Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094\u20137.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6098_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3343\/alm.2016.36.6.603","volume":"36","author":"JE Park","year":"2016","unstructured":"Park JE, Kim JY, Yun SA, Lee MK, Huh HJ, Kim JW, et al. Performance Evaluation of the Real-Q Cytomegalovirus (CMV) Quantification Kit Using Two Real-Time PCR Systems for Quantifying CMV DNA in Whole Blood. Ann Lab Med. 2016;36(6):603\u20136.","journal-title":"Ann Lab Med"},{"issue":"1","key":"6098_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/clinids\/24.1.52","volume":"24","author":"M Eddleston","year":"1997","unstructured":"Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 1997;24(1):52\u20136.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"6098_CR18","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1097\/CCM.0b013e31818f3fc4","volume":"36","author":"M Ziemann","year":"2008","unstructured":"Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008;36(12):3145\u201350.","journal-title":"Crit Care Med"},{"issue":"2","key":"6098_CR19","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/cc10069","volume":"15","author":"A Heininger","year":"2011","unstructured":"Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15(2):R77.","journal-title":"Crit Care"},{"issue":"8","key":"6098_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3855\/jidc.1487","volume":"5","author":"M Jain","year":"2011","unstructured":"Jain M, Duggal S, Chugh TD. Cytomegalovirus infection in non-immunosuppressed critically ill patients. J Infect Dev Ctries. 2011;5(8):571\u20139.","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"6098_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/01.CIR.0000044940.65226.1F","volume":"107","author":"M Smieja","year":"2003","unstructured":"Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(2):251\u20137.","journal-title":"Circulation"},{"issue":"6","key":"6098_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/cis993","volume":"56","author":"O Manuel","year":"2013","unstructured":"Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817\u201324.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"6098_CR23","first-page":"2386","volume":"71","author":"S-H Kim","year":"2020","unstructured":"Kim S-H. Interferon-\u03b3 Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice? Clin Infect Dis. 2020;71(9):2386\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6098_CR24","first-page":"557","volume":"29","author":"S Seo","year":"2009","unstructured":"Seo S, Cho Y, Park J. Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. Korean J Lab Med. 2009;29(6):557\u201362.","journal-title":"Korean J Lab Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06098-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T21:04:56Z","timestamp":1620162296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06098-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6098"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06098-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Konkuk university of medical center(#2020\u201304-040). The study was performed in accordance with the guidelines followed as per the Declaration of Helsinki. Informed consent was waived by the IRB of Konkuk university of medical center since the electronic medical record was reviewed retrospectively with de-personalized identification number.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication and sharing our data was obtained in association with consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"414"}}